In heart failure with reduced ejection fraction, edema and congestion are related to reduced
cardiac function. Edema and congestion are further aggravated by chronic kidney failure …

Despite recent advances in chronic heart failure (HF) management, the prognosis of HF
patients is poor. This highlights the need for researching new drugs targeting, beyond …

There is need for a reliable in vitro system that can accurately replicate the cardiac
physiological environment for drug testing. The limited availability of human heart tissue …

Aims New drugs for heart failure (HF) that target restoring the impaired NO-sGC-cGMP
pathway are being developed. We aimed to investigate the effects of vericiguat, an sGC …

Hypertrophic cardiomyopathy (HCM) is a cardiac muscle disorder characterized by
generally asymmetric abnormal hypertrophy of the left ventricle without abnormal loading …

Cardiac remodelling is an adverse phenomenon linked to heart failure progression and an
important contributor to heart failure severity. Cardiac remodelling could represent the real …

Heart failure (HF) is a progressively deteriorating medical condition that significantly reduces
both the patients' life expectancy and quality of life. Even though real progress was made in …

Heart failure (HF) is one of the most critical health and economic burdens worldwide, and its
prevalence is continuously increasing. HF is a disease that occurs due to a pathological …

Aims Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i) represent a unique class of
anti‐hyperglycaemic agents for type 2 diabetes mellitus that selectively inhibit renal glucose …

Heart failure management has been repeatedly reviewed over time. This strategy has
resulted in improved quality of life, especially in patients with heart failure with reduced …